Diabetes
Diabetes mellitus is a chronic disease accounting for 90% of all diagnosed diabetes cases and is mainly characterised by elevated blood glucose levels resulting from defects in insulin secretion and insulin action.
Type 2 diabetes mellitus - a 21st Century Epidemic
Type 2 diabetes mellitus accounts for 90% of all diagnosed diabetes cases, and typically develops in middle-aged adults. The type 2 diabetes mellitus etiology is complex and include both genetic and environmental factors, as older age, obesity, family history of diabetes, physical inactivity, and race/ethnicity. Moreover, diabetes is frequently associated with a high body mass index, hypertension, and high serum cholesterol levels, leading to a dangerous combination of risk factors that promote the development of cardiovascular disease. In addition, various and severe T2DM complications increase diabetes morbidity: atherosclerosis, retinopathy, microangiopathy, neuropathy, renal dysfunction, cardiac abnormality...
Market
It is estimated that over 180 million people globally have diabetes with over 20 million sufferers in the US alone.
Products
Medesis Pharma is addressing type 2 diabetes mellitus with two products currently in development: NP01: A new pharmaceutical product based upon vanadium and Aonys. NP01 improves insulin sensitivity leading to insulin-sensitisation of peripheral tissues. As a consequence, glucose homeostasis is dramatically improved with better glucose uptake in insulin target tissues such as: skeletal muscle, liver and adipose tissue. Hepatic glucose output is reduced, whereas glycolysis and lipogenesis are enhanced.
